Logo image of BLCO

BAUSCH + LOMB CORP (BLCO) Stock Fundamental Analysis

NYSE:BLCO - New York Stock Exchange, Inc. - CA0717051076 - Common Stock - Currency: USD

13.88  +0.12 (+0.87%)

Fundamental Rating

3

Taking everything into account, BLCO scores 3 out of 10 in our fundamental rating. BLCO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. BLCO has a medium profitability rating, but doesn't score so well on its financial health evaluation. While showing a medium growth rate, BLCO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BLCO was profitable.
In the past year BLCO had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BLCO reported negative net income in multiple years.
BLCO had a positive operating cash flow in 4 of the past 5 years.
BLCO Yearly Net Income VS EBIT VS OCF VS FCFBLCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

BLCO has a Return On Assets of -2.70%. This is in the better half of the industry: BLCO outperforms 68.98% of its industry peers.
BLCO's Return On Equity of -5.69% is fine compared to the rest of the industry. BLCO outperforms 70.59% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.86%, BLCO is in the better half of the industry, outperforming 66.84% of the companies in the same industry.
BLCO had an Average Return On Invested Capital over the past 3 years of 1.59%. This is significantly below the industry average of 7.89%.
Industry RankSector Rank
ROA -2.7%
ROE -5.69%
ROIC 0.86%
ROA(3y)-1.41%
ROA(5y)-0.54%
ROE(3y)-2.87%
ROE(5y)-1.37%
ROIC(3y)1.59%
ROIC(5y)1.92%
BLCO Yearly ROA, ROE, ROICBLCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4

1.3 Margins

The Operating Margin of BLCO (2.63%) is better than 66.84% of its industry peers.
BLCO's Operating Margin has declined in the last couple of years.
BLCO has a Gross Margin (60.03%) which is comparable to the rest of the industry.
BLCO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.63%
PM (TTM) N/A
GM 60.03%
OM growth 3Y-22.07%
OM growth 5Y-17.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-1.25%
BLCO Yearly Profit, Operating, Gross MarginsBLCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BLCO is destroying value.
Compared to 1 year ago, BLCO has more shares outstanding
The number of shares outstanding for BLCO has been increased compared to 5 years ago.
BLCO has a worse debt/assets ratio than last year.
BLCO Yearly Shares OutstandingBLCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
BLCO Yearly Total Debt VS Total AssetsBLCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

BLCO has an Altman-Z score of 0.81. This is a bad value and indicates that BLCO is not financially healthy and even has some risk of bankruptcy.
BLCO's Altman-Z score of 0.81 is in line compared to the rest of the industry. BLCO outperforms 47.06% of its industry peers.
BLCO has a Debt/Equity ratio of 0.75. This is a neutral value indicating BLCO is somewhat dependend on debt financing.
BLCO has a Debt to Equity ratio of 0.75. This is in the lower half of the industry: BLCO underperforms 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z 0.81
ROIC/WACC0.1
WACC8.92%
BLCO Yearly LT Debt VS Equity VS FCFBLCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

BLCO has a Current Ratio of 1.56. This is a normal value and indicates that BLCO is financially healthy and should not expect problems in meeting its short term obligations.
BLCO has a Current ratio of 1.56. This is in the lower half of the industry: BLCO underperforms 74.87% of its industry peers.
A Quick Ratio of 0.96 indicates that BLCO may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.96, BLCO is doing worse than 78.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 0.96
BLCO Yearly Current Assets VS Current LiabilitesBLCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BLCO have decreased strongly by -32.39% in the last year.
The Revenue has grown by 11.94% in the past year. This is quite good.
Measured over the past years, BLCO shows a small growth in Revenue. The Revenue has been growing by 4.87% on average per year.
EPS 1Y (TTM)-32.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)11.94%
Revenue growth 3Y8.36%
Revenue growth 5Y4.87%
Sales Q2Q%3.46%

3.2 Future

The Earnings Per Share is expected to grow by 24.11% on average over the next years. This is a very strong growth
Based on estimates for the next years, BLCO will show a small growth in Revenue. The Revenue will grow by 4.45% on average per year.
EPS Next Y-18.2%
EPS Next 2Y12.29%
EPS Next 3Y19.54%
EPS Next 5Y24.11%
Revenue Next Year5.39%
Revenue Next 2Y5.44%
Revenue Next 3Y5.22%
Revenue Next 5Y4.45%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BLCO Yearly Revenue VS EstimatesBLCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
BLCO Yearly EPS VS EstimatesBLCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 28.92, which means the current valuation is very expensive for BLCO.
75.94% of the companies in the same industry are more expensive than BLCO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BLCO to the average of the S&P500 Index (27.45), we can say BLCO is valued inline with the index average.
BLCO is valuated rather expensively with a Price/Forward Earnings ratio of 17.75.
Based on the Price/Forward Earnings ratio, BLCO is valued a bit cheaper than the industry average as 79.68% of the companies are valued more expensively.
BLCO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.90, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 28.92
Fwd PE 17.75
BLCO Price Earnings VS Forward Price EarningsBLCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BLCO is valued a bit cheaper than the industry average as 77.01% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 17.05
BLCO Per share dataBLCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A more expensive valuation may be justified as BLCO's earnings are expected to grow with 19.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.29%
EPS Next 3Y19.54%

More info and screens

0

5. Dividend

5.1 Amount

BLCO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BAUSCH + LOMB CORP

NYSE:BLCO (7/3/2025, 7:05:10 PM)

13.88

+0.12 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/bmo
Earnings (Next)N/A N/A
Inst Owners10.83%
Inst Owner Change5.62%
Ins Owners0.45%
Ins Owner Change20.17%
Market Cap4.91B
Analysts72.63
Price Target15.09 (8.72%)
Short Float %6.29%
Short Ratio3.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-178.13%
Min EPS beat(2)-360.35%
Max EPS beat(2)4.09%
EPS beat(4)3
Avg EPS beat(4)-86.35%
Min EPS beat(4)-360.35%
Max EPS beat(4)6.68%
EPS beat(8)6
Avg EPS beat(8)-34.35%
EPS beat(12)9
Avg EPS beat(12)-16.97%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.61%
Min Revenue beat(2)-3.07%
Max Revenue beat(2)-0.16%
Revenue beat(4)1
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-3.07%
Max Revenue beat(4)1.93%
Revenue beat(8)4
Avg Revenue beat(8)1.13%
Revenue beat(12)7
Avg Revenue beat(12)0.92%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.08%
PT rev (3m)-24.15%
EPS NQ rev (1m)-6.34%
EPS NQ rev (3m)-50.21%
EPS NY rev (1m)1.15%
EPS NY rev (3m)-25.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.93%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.41%
Valuation
Industry RankSector Rank
PE 28.92
Fwd PE 17.75
P/S 1.02
P/FCF N/A
P/OCF 29.55
P/B 0.77
P/tB N/A
EV/EBITDA 17.05
EPS(TTM)0.48
EY3.46%
EPS(NY)0.78
Fwd EY5.63%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)0.47
OCFY3.38%
SpS13.66
BVpS18
TBVpS-4.62
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.7%
ROE -5.69%
ROCE 1.09%
ROIC 0.86%
ROICexc 0.87%
ROICexgc 2.86%
OM 2.63%
PM (TTM) N/A
GM 60.03%
FCFM N/A
ROA(3y)-1.41%
ROA(5y)-0.54%
ROE(3y)-2.87%
ROE(5y)-1.37%
ROIC(3y)1.59%
ROIC(5y)1.92%
ROICexc(3y)1.64%
ROICexc(5y)1.97%
ROICexgc(3y)5.47%
ROICexgc(5y)6.76%
ROCE(3y)2.02%
ROCE(5y)2.43%
ROICexcg growth 3Y-21.86%
ROICexcg growth 5Y-17.06%
ROICexc growth 3Y-20.45%
ROICexc growth 5Y-15.79%
OM growth 3Y-22.07%
OM growth 5Y-17.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-1.25%
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Debt/EBITDA 8.57
Cap/Depr 77.31%
Cap/Sales 6.92%
Interest Coverage 250
Cash Conversion 29.7%
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 0.96
Altman-Z 0.81
F-Score3
WACC8.92%
ROIC/WACC0.1
Cap/Depr(3y)53.43%
Cap/Depr(5y)52.81%
Cap/Sales(3y)5.03%
Cap/Sales(5y)5.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y-18.2%
EPS Next 2Y12.29%
EPS Next 3Y19.54%
EPS Next 5Y24.11%
Revenue 1Y (TTM)11.94%
Revenue growth 3Y8.36%
Revenue growth 5Y4.87%
Sales Q2Q%3.46%
Revenue Next Year5.39%
Revenue Next 2Y5.44%
Revenue Next 3Y5.22%
Revenue Next 5Y4.45%
EBIT growth 1Y-42.79%
EBIT growth 3Y-15.55%
EBIT growth 5Y-13.93%
EBIT Next Year40.8%
EBIT Next 3Y21.5%
EBIT Next 5Y15.15%
FCF growth 1Y-244.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.96%
OCF growth 3Y-35.71%
OCF growth 5Y-21.91%